Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Tenofovir Alafenamide in Virologically Suppressed Chronic Hepatitis B
NCT02979613Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of tenofovir alafenamide in Chronic Hepatitis B (CHB) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Percentage of Participants With Hepatitis B Virus (HBV) DNA Levels >= 20 IU/mL at 48 weeks. Started Dec 2016; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02979613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02979613.